and Hong Kong (n=1) agreed to participate. Human Research Ethics Committee approval was obtained at all centres and the requirement for informed consent was waived as the study was considered a quality assurance exercise.
All consecutive adult patients presenting for cardiac surgery in the month of November 2004 were included. Eligible surgery included CABG surgery, valve repair or replacement, cardiac tumour resection, cardiac transplantation, ventricular assist device insertion or central extra-corporeal membrane oxygenation (ECMO) and aortic surgery with cardiopulmonary bypass (CPB). We excluded those undergoing minor or intermediate procedures: sternal debridement, ECMO support via femoral cannulation (alone), pericardial procedures, cardiac biopsy or pacemaker insertion. Patients who were returned to the operating theatre within one week of primary surgery were also excluded.
We collected data on patient demographics and comorbidities, surgical and anaesthetic procedures, blood loss and blood transfusion practices. The cardiac anaesthetist prospectively collected these data at the time of surgery; missing data were retrieved via a medical record review by the site coordinator. Thirty-day morbidity and mortality data were collected by medical record review and telephone contact with the patient on or after day primary CABG (the most prevalent type of cardiac surgery) and valvular/other surgeries.
Blood loss was measured as postoperative mediastinal drainage. Although this approach is commonly used in cardiac surgery 7 , it has the limitation that it does not include blood lost intraoperatively or blood discarded with the CPB circuit.
We used the following transfusion terms: Red cell transfusion-the transfusion of packed red blood cells or whole blood. Figure 1 ); 15% of patients had taken clopidogrel within seven days of surgery.
Two-thirds of patients (329/498) were administered full-dose, 6% half-dose], tranexamic acid 25%) ( Table 2 ). of surgery, had no apparent effect on bleeding: total mediastinal blood loss, aspirin 670 (466-1216) ml versus no aspirin 700 (463-1175) ml, P=0.84 (Table 3 ). 
Last aspirin (days)
Anaesthesia and Intensive Care, Vol. 35, No. 5, October 2007 The overall blood transfusion rate was 57% (284/498), with red cell transfusion used in 49% (244/498) and component transfusion used in 27% transfusion rates between centres (range 17 to 79%, P <0.001) ( Figure 2 ). The majority of patients who received red cell transfusion were given only one or two units ( Figure 3 ).
The association between antiplatelet or anticoagulant therapy and transfusion is demonstrated in Table 4 . Recent clopidogrel therapy was associated with increased component transfusion. Recent aspirin or warfarin exposure did not affect the rate of red cell or other transfusion (transfusion rate aspirin patients 58.3% vs. transfusion rate for nonaspirin patients 56.5%, P=0.69).
We estimated the transfusion trigger using the lowest haemoglobin level in patients who received red cell transfusion. Intraoperatively, the lowest (Table 5 ). Factors associated with transfusion and reoperation for excessive bleeding include pre-existing renal impairment, clopidogrel therapy, high risk procedure and complex (other than primary CABG) ( Table 6 ). Emergency surgery was associated with increased reoperation for excessive bleeding. 
Number of red cell units

DISCUSSION
Clinicians caring for cardiac surgical patients are faced with an increasing proportion of patients of advanced age and complexity. Our study demonstrates that the transfusion of allogeneic blood products is a common intervention in cardiac surgery and that preoperative or antiplatelet agents (clopidogrel but not aspirin) are associated with increased rates of transfusion.
In our study, about half (49%) of all cardiac surgical patients received a red cell transfusion. The purported link between transfusion and worse outcome raises some concern 4,5,8 . However, severe anaemia has its own complications including increased risk of death 9 . Blood transfusion may be associated with immunosuppression, ABO incompatibility, transfusion-related acute lung injury and an overall worse outcome that is multifactorial and complex due to microcirculation dysfunction 10 . Platelet transfusion may increase the risk of stroke and death 11 .
An observation study of 11,963 CABG surgery patients over a seven-year period at the Cleveland Clinic in the U.S.A. 6 .87]). The mortality increase was evident one year out from cardiac surgery. Mortality related to transfusion was dose-dependent: the more a patient received, the worse was the survival curve. However this study, despite using propensity matching to control for confounding, is prone to bias. The observed associations require randomised trials to demonstrate causation, but such trials of blood transfusion are rare. Hebert et al 12 conducted the largest randomised trial of transfusion to date, in 838 patients managed in an intensive care unit. In this landmark study patients were randomly allocated to receive red cell transfusion at a transfusion trigger of either 70 g/l (restrictive group) or 100 g/l (liberal group). Their data showed a trend towards lower overall mortality in their restrictive group, 19% vs. 23%, P=0.11. Also the mortality rate during hospitalisation was 22% vs. 28%, P=0.05. The results of this trial have led to a more restrictive transfusion policy becoming a standard of care in critically ill patients. However, a later publication reporting on a subgroup of patients with severe coronary artery disease found that the restrictive group had poorer, but nonliberal group 13 . This has led to a higher transfusion trigger, typically 90 g/l, in patients with coronary artery disease.
Recent randomised trials evaluating the use of leucodepleted red cell transfusion in cardiac surgery have shown at least a 50% reduction in infection and mortality with this intervention 14, 15 . Leucodepletion has subsequently been recommended as a standard for cardiac surgery patients 10 .
Options for reducing transfusion in surgery include optimising red cell mass preoperatively, reducing blood loss, restrictive transfusion policy and utilisation of blood substitutes. Although the investigation, the Society of Thoracic Surgeons and Society of Cardiovascular Anesthesiologists have recently published guidelines for blood transfusion and conservation 10 . Key recommendations include:
Drugs that increase preoperative blood volume (e.g. erythropoietin) or decrease postoperative bleeding (e.g. antifibrinolytics).
Devices that conserve blood (e.g. intraoperative blood salvage and blood sparing interventions).
Interventions that protect the patients own blood from the stress of operation (e.g. autologous predonation and normovolaemic haemodilution). Consensus, institution-specific blood transfusion algorithms supplemented with point-of-care testing.
Most importantly, a multimodal approach to blood conservation combining all of the above. There is good rationale for preoperative optimisation of red cell mass. In some circumstances, a delay in surgery may be warranted to allow treatment with iron, folate and possibly erythropoietin 10 . However in our study, 40% of cardiac surgical patients were non-elective, effectively interventions.
In our study many patients presenting for surgery were receiving antiplatelet and other medications that impair coagulation and increase blood loss. There is a paucity of data to establish the true perioperative period.
We found that recent aspirin therapy had no measurable effect on blood loss in this cardiac surgical population. Aspirin impairs platelet function 16 and so could reduce further risk of myocardial 1.
2.
3.
4.
5.
infarction or stroke, and graft thrombosis 17 , but in other studies has a small effect on bleeding 18 . It is routine practice in most cardiac surgical units to elective cardiac surgery. But, as was demonstrated in our study, contemporary cardiac surgical practice often does not allow an opportunity for this to occur because of the shortened time between presentation with an acute coronary syndrome and surgery. Bélisle and Hardy 18 reviewed more than 50 studies including more than 10,000 patients, as well as data from 5,426 patients. They concluded that although aspirin therapy increases postoperative blood loss, it was by less than 300 ml and therefore should not increase the use of blood products if a strict transfusion protocol were followed. A large randomised trial of aspirin administration in cardiac surgery is warranted to evaluate whether the proposed increase in bleeding and possibly transfusion.
In contrast to aspirin, we found that recent exposure to clopidigrel was a risk factor for blood transfusion and in particular for component transfusion, despite most of these patients receiving 19 studied 224 consecutive patients undergoing primary elective CABG and compared those with preoperative clopidogrel exposure within seven days (n=59) to those without exposure (n=165). The clopidogrel group had greater blood loss and transfusion requirements and a tenfold increase in re-operation for bleeding (6.8% vs. 0.6%, P=0.018). These administration of clopidogrel for coronary stenting in patients subsequently needing CABG surgery. study, particularly in non-CABG surgery. This may settings and with aprotinin use and graft patency in CABG surgery 7, 20 . Our survey design cannot reliably investigate the relationship between blood loss, Several recent meta-analyses of randomised trials blood loss, the need for blood transfusion and re-operation for bleeding in many types of cardiac surgery [21] [22] [23] effect on mortality 22 . However, despite this high level therapy may increase the risk of complications after cardiac surgery 7, 20, 24 . The three main safety issues reactions, renal dysfunction and potential thrombotic events. One controversial study has raised major safety concerns with aprotinin 24 . This retrospective observational study used propensity matching and multivariable logistic regression techniques to attempt to compensate for confounding introduced because of lack of randomisation. Despite this, the possibility exists that not all bias was eliminated 25 . Such studies are useful in generating hypotheses, but lack certainty in their results. More should be available from several trials currently underway.
Allogenic blood product administration is associated with morbidity and mortality in cardiac surgery [4] [5] [6] 8, 10, 11 . In our region, more than half of cardiac surgery patients receive a blood transfusion. We found that intraoperative red cell transfusion occurred at a haemoglobin level of 66 (61-73) mg/l and postoperative red cell transfusion occurred at a haemoglobin level of 79 (74-85) mg/l. These results are reassuring and in keeping with existing guidelines 10, 18 . There was wide variation in the rate of transfusion between centres in our study, as has been reported elsewhere 26 , supporting a need for transfusion guidelines. The require evaluation in large randomised trials.
